Treatment of HER2-Dependent Cancers by SORL1 Inhibition

摘要

This disclosure relates to the field of cancer therapeutics. Exemplary embodiments relate to agents that inhibit expression of SORL1, a gene encoding for Sortilin related protein family-A (SORLA) or the function of SORLA protein, a multifunctional protein belonging to sortilin and LDL-receptor families, and to methods for their use in treating HER2-dependent cancers.